Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $361.15M · View financials
Snapshot Sep 9, 2026, 4:00 PM ET
FY 2026 · View financials
Decision snapshot: OCGN stock price vs S: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at S's multiple
Needs Annual EPS, S P/E.
Implied fair value · at OCGN's multiple
Needs Annual EPS is negative, OCGN P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
11 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
OCUGEN, INC. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
SENTINELONE, INC · implied price per share
At least 3 of the last 5 annual free-cash-flow observations must be positive.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
IOVANCE BIOTHERAPEUTICS, INC.
OCGN vs IOVA
bluebird bio, Inc.
OCGN vs BLUE
BioNTech SE
OCGN vs BNTX
Moderna, Inc.
OCGN vs MRNA
Legend Biotech Corp
OCGN vs LEGN
Arcturus Therapeutics Holdings Inc.
OCGN vs ARCT
Palo Alto Networks Inc
OCGN vs PANW
Zscaler, Inc.
OCGN vs ZS
CHECK POINT SOFTWARE TECHNOLOGIES LTD
OCGN vs CHKP
CrowdStrike Holdings, Inc.
OCGN vs CRWD
Fortinet, Inc.
OCGN vs FTNT
Okta, Inc.
OCGN vs OKTA
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Edwyn research
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe OCGN can rapidly improve commercialization and convert its small revenue base into materially better margins, then consider holding only selectively; otherwise, the data favors avoiding or reducing exposure because the P/S-based implied value is far below the current price and quality scores are weak.
OCGN trades at 115.8x P/S and 117.9x EV/Revenue versus S at 5.8x P/S and 5.2x EV/Revenue, implying a very large valuation gap despite OCGN's much smaller revenue base. The provided P/S framework implies a price of $0.08 versus the current $1.51, or -94.9% downside, although OCGN is also within its historical band of $1.36 to $1.66.
Supporting Metrics
